Italian biopharma, Chiesi Group, and Key2Brain, a Swedish biotech, have agreed to advance the development of two blood-brain barrier (BBB)-crossing recombinant enzyme replacement therapies (ERT) for lysosomal storage disorders. These are ultra-rare diseases, including alpha-mannosidosis and Krabbe disease, that affect the central nervous system and have limited treatment options. Key2Brain will provide Chiesi with a […]
The post Chiesi partners with Key2Brain to develop therapies for rare neurodegenerative diseases appeared first on Pharmafile.
